Span Divergent

Who are the top shareholders of the Span Divergent?

The top shareholders of Span Divergent are Pradipkumar Keshavlal Desai with 42.77%, and Bhartiben Natwerlal Patel, the largest public shareholder, with 10.53%. Individual investors hold a combined 14.97%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Span Divergent include Pradipkumar Keshavlal Desai, who holds the largest share at 42.77%. The highest public shareholder is Bhartiben Natwerlal Patel, with a holding of 10.53%. Additionally, individual investors collectively hold 14.97% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Who are in the management team of Span Divergent?

As of March 2023, the management team of Span Divergent includes Shyamal Ghosh, Sanjay N Mehta, Kamlesh Patel, Pradip K Desai, Viral Pradipkumar Desai, Paras Desa, N Gopalaswami, Shefali Desai, Urvi Shinde, Jigneshkumar R Desai, and Nirav D Jogani, featuring a mix of executive and non-executive members.

As of March 2023, the management team of Span Divergent includes the following members:<BR><BR>1. Shyamal Ghosh - Non-Executive & Independent Director<BR>2. Sanjay N Mehta - Non-Executive & Non-Independent Director<BR>3. Kamlesh Patel - Non-Executive & Independent Director<BR>4. Pradip K Desai - Non-Executive & Non-Independent Director<BR>5. Viral Pradipkumar Desai - Managing Director<BR>6. Paras Desa - Whole Time Director & CFO<BR>7. N Gopalaswami - Chairman & Independent Director<BR>8. Shefali Desai - Non-Executive Director<BR>9. Urvi Shinde - Company Secretary & Compliance Officer<BR>10. Jigneshkumar R Desai - Independent Director<BR>11. Nirav D Jogani - Independent Director<BR><BR>This team comprises a mix of executive and non-executive members, with various roles contributing to the governance and management of the company.

What does Span Divergent do?

Span Divergent Ltd is a micro-cap pharmaceutical company focused on diagnostic reagents, with recent quarterly net sales of 1 Cr and a net profit of -1 Cr as of March 2025. The company has a market cap of Rs 12 Cr and operates with a negative debt-equity ratio.

Overview:<BR>Span Divergent Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of microbiological, immunological, and biochemical diagnostic reagents and related products.<BR><BR>History:<BR>Span Divergent Ltd was incorporated on 31st March 1980 and transitioned from a Private Limited Company to a Public Limited Company on 14th August 1993. The latest reported quarterly results indicate net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 12 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 53 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.36 <BR>Return on Equity: 34.88% <BR>Price to Book: -4.18 <BR><BR>Contact Details:<BR>Address: 9th Fl 902-904 Rajhans Bonista, Ghod Dod Road Surat Gujarat : 395007 <BR>Tel: 91-261-2663232 <BR>Email: secretarial@span.co.in <BR>Website: http://www.span.in

What is the bonus history of the Span Divergent?

Span Divergent issued a 1:1 bonus on July 27, 2010, with a record date of July 28, 2010, making shareholders eligible for the bonus shares. This is the most recent bonus action recorded for the company.

Span Divergent has a bonus history that includes a 1:1 bonus issue announced on July 27, 2010. The record date for this bonus was July 28, 2010, meaning that shareholders on this date were eligible to receive the bonus shares. This was the latest recorded bonus action for the company. If you have any more questions about Span Divergent or its financial activities, feel free to ask!

Has Span Divergent declared dividend?

Span Divergent Ltd has declared a 5% dividend, amounting to $0.5 per share, but the dividend yield is 0%. While the company has shown significant price returns over longer periods, recent performance has been negative, with total returns reflecting this variability.

Span Divergent Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: Jul-16-2013<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -39.62%, the dividend return was 0%, resulting in a total return of -39.62%.<BR><BR>In the 1-year period, the price return was -10.61%, the dividend return was 0%, leading to a total return of -10.61%.<BR><BR>Over the 2-year period, the price return was 50.47%, with a dividend return of 0%, culminating in a total return of 50.47%.<BR><BR>In the 3-year period, the price return was 48.0%, the dividend return was 0%, which resulted in a total return of 48.0%.<BR><BR>For the 4-year period, the price return was 61.21%, the dividend return was 0%, yielding a total return of 61.21%.<BR><BR>Finally, in the 5-year period, the price return was 124.13%, with a dividend return of 0%, achieving a total return of 124.13%.<BR><BR>Overall, while Span Divergent Ltd has declared a dividend, the dividend yield remains at 0%, indicating that the dividend has not contributed to returns in recent periods. The total returns show significant variability, with positive returns over longer periods despite recent negative performance.

Who are the peers of the Span Divergent?

The peers of Span Divergent include Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Sun Pharma.Inds., Cipla, and Dr Reddy's Labs exhibit excellent management and growth, while Divi's Lab. has the highest 1-year return at 51.69%, and Cian Healthcare has the lowest at -82.59%.

Peers: The peers of Span Divergent are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Unjha Formul., Checkpoint Trend, Vivanza Biosci., Cian Healthcare, and Beryl Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is noted at Unjha Formul., and Below Average management risk is seen at Checkpoint Trend, Vivanza Biosci., Cian Healthcare, and Beryl Drugs. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Unjha Formul., Checkpoint Trend, Vivanza Biosci., Cian Healthcare, and Beryl Drugs. Excellent capital structure is present at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Torrent Pharma and Unjha Formul., and the rest have Below Average capital structure.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Cian Healthcare has the lowest at -82.59%. Span Divergent's own 1-year return is -26.41%, which is significantly lower than Divi's Lab. and higher than Cian Healthcare. Additionally, Unjha Formul., Checkpoint Trend, Vivanza Biosci., Cian Healthcare, and Beryl Drugs all have negative six-month returns.

Is Span Divergent overvalued or undervalued?

As of April 25, 2023, Span Divergent is considered overvalued and "risky" due to negative financial ratios and poor performance compared to peers, with a year-to-date decline of 35.20% against a 5.61% gain in the Sensex.

As of 25 April 2023, Span Divergent has moved from a grade of "does not qualify" to "risky." The company is currently overvalued based on its negative financial ratios, including a PE ratio of -12.33, an EV to EBITDA of -13.34, and an EV to Capital Employed of -7.41. These figures indicate significant financial distress, particularly with negative capital employed and book value.<BR><BR>In comparison to its peers, Span Divergent's valuation metrics are starkly unfavorable. For instance, Poly Medicure has a PE ratio of 66.7 and an EV to EBITDA of 47.56, while Blue Jet Health shows a PE ratio of 51.29 and an EV to EBITDA of 40.68, both indicating a much stronger financial position. Despite a recent stock return of 10.04% over the past week, the longer-term performance remains concerning, with a year-to-date decline of 35.20% compared to a 5.61% gain in the Sensex. This further reinforces the view that Span Divergent is overvalued in its current state.

What is the technical trend for Span Divergent?

As of June 5, 2025, the technical trend for Span Divergent has shifted to a moderately strong bearish stance, supported by bearish signals from the weekly MACD, KST, and daily moving averages, while the RSI indicates a lack of momentum.

As of 5 June 2025, the technical trend for Span Divergent has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD and KST both showing bearish signals, along with daily moving averages confirming a bearish trend. The Bollinger Bands and Dow Theory also reflect a mildly bearish outlook on both weekly and monthly time frames. The RSI shows no signal, indicating a lack of momentum in either direction. Overall, the technical indicators suggest a continued bearish sentiment in the near term.

How big is Span Divergent?

As of 24th July, Span Divergent Ltd has a market capitalization of 12.00 Cr and reported net sales of 8.96 Cr with a net loss of 0.92 Cr for the latest four quarters. Shareholder's funds were at a loss of 1.89 Cr, and total assets were valued at 23.77 Cr.

As of 24th July, Span Divergent Ltd has a market capitalization of 12.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported net sales of 8.96 Cr. However, it experienced a loss of 0.92 Cr in net profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024. Shareholder's funds stood at a loss of 1.89 Cr, while total assets were valued at 23.77 Cr.

Are Span Divergent latest results good or bad?

Span Divergent's latest results are largely negative, showing a consolidated net loss of ₹0.13 crores, despite significant revenue growth of 614.95%. The company faces ongoing operational challenges and a lack of investor confidence, indicating a precarious financial position.

Span Divergent's latest results present a mixed picture, but overall, they lean towards the negative side. In Q2 FY26, the company reported a consolidated net loss of ₹0.13 crores, which is a 30% increase in losses compared to the previous quarter. This indicates that while the company is still struggling to achieve profitability, its financial health has not improved.<BR><BR>On a more positive note, the company experienced significant revenue growth, with net sales reaching ₹7.65 crores, marking a remarkable 614.95% increase from the previous quarter and a 173.21% increase year-on-year. However, this spike in revenue raises concerns about sustainability, as the company has a history of inconsistent sales performance.<BR><BR>Despite the revenue growth, operational efficiency remains a critical issue. The operating margin, excluding other income, was just 0.13%, which is barely positive and reflects ongoing challenges in converting sales into profits. Additionally, the profit after tax (PAT) margin was negative at -2.51%, further highlighting the company's struggles.<BR><BR>Furthermore, Span Divergent has been grappling with a negative book value and a working capital deficit, which raises questions about its long-term viability. The absence of institutional interest in the stock also reflects a lack of confidence in its recovery prospects.<BR><BR>In summary, while the revenue growth is a positive sign, the widening losses and persistent operational challenges suggest that the overall results are not good for Span Divergent. The company remains in a precarious financial position, and significant improvements are needed to restore investor confidence.

How has been the historical performance of Span Divergent?

Span Divergent has experienced a significant decline in net sales and profitability from Mar'19 to Mar'25, with losses reported in both profit before tax and profit after tax in Mar'25. Despite a decrease in total liabilities and assets, the company faces ongoing challenges in revenue generation and profitability.

Answer:<BR>The historical performance of Span Divergent shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Span Divergent's net sales have seen a significant decline from 24.14 Cr in Mar'19 to 8.96 Cr in Mar'25, with a notable drop from 12.66 Cr in Mar'24. The total operating income followed a similar pattern, decreasing from 24.14 Cr in Mar'19 to 8.96 Cr in Mar'25. The operating profit (PBDIT) has also been inconsistent, with a peak of 3.07 Cr in Mar'24 but falling to 0.56 Cr in Mar'25. The profit before tax has fluctuated, showing a loss of 1.08 Cr in Mar'25 compared to a profit of 0.80 Cr in Mar'24. The profit after tax reflects a loss of 1.27 Cr in Mar'25, down from a profit of 0.78 Cr in Mar'24. The company's total liabilities decreased from 39.33 Cr in Mar'20 to 22.84 Cr in Mar'25, while total assets also declined from 39.33 Cr to 22.84 Cr over the same period. Cash flow from operating activities has remained relatively stable, with 1.00 Cr reported in Mar'25, consistent with the previous year. Overall, Span Divergent's financial performance indicates challenges, particularly in revenue generation and profitability, with a trend of increasing losses in recent years.

How has been the historical performance of Span Divergent?

Span Divergent has experienced a significant decline in net sales and operating income from 24.14 Cr in Mar'19 to 8.96 Cr in Mar'25, with consistent negative profits and fluctuating expenditures. The company has struggled with profitability and sales growth over the years.

Answer:<BR>The historical performance of Span Divergent shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Span Divergent's net sales have declined from 24.14 Cr in Mar'19 to 8.96 Cr in Mar'25, with a notable drop from 12.66 Cr in Mar'24 and 12.53 Cr in Mar'23. The total operating income followed a similar trend, decreasing from 24.14 Cr in Mar'19 to 8.96 Cr in Mar'25. The company has consistently reported no other operating income. Total expenditure, excluding depreciation, has also decreased from 31.42 Cr in Mar'19 to 9.59 Cr in Mar'25. Operating profit (PBDIT) has shown volatility, with a negative value of -0.63 Cr in Mar'25, compared to a positive 3.07 Cr in Mar'24. Profit before tax has fluctuated significantly, moving from -13.47 Cr in Mar'19 to -1.08 Cr in Mar'25. Consequently, the profit after tax has also been negative, reaching -1.27 Cr in Mar'25, down from 0.78 Cr in Mar'24. The company's total liabilities decreased from 39.33 Cr in Mar'20 to 22.84 Cr in Mar'25, while total assets followed a similar downward trend from 39.33 Cr in Mar'20 to 22.84 Cr in Mar'25. Cash flow from operating activities has remained relatively stable, with 1.00 Cr in Mar'25, consistent with the previous year. Overall, Span Divergent has faced challenges in maintaining profitability and sales growth over the years.

When is the next results date for Span Divergent Ltd?

The next results date for Span Divergent Ltd is 10 February 2026.

The next results date for Span Divergent Ltd is scheduled for 10 February 2026.

Should I buy, sell or hold Span Divergent Ltd?

Why is Span Divergent Ltd falling/rising?

As of 31-Mar, Span Divergent Ltd's stock price is stable at Rs. 34.93, with a 21.66% return over the past year. However, erratic trading, declining investor participation, and fundamental weaknesses raise concerns about its future sustainability.

As of 31-Mar, Span Divergent Ltd's stock price is currently stable at Rs. 34.93, showing no change (0.00%). Despite this stability in the current price, the stock has demonstrated a significant upward trend over the past year, with a return of 21.66%, outperforming the BSE500 index, which has declined by 7.06% during the same period. Additionally, the stock has achieved a new 52-week high today, indicating positive momentum.<BR><BR>However, there are several factors contributing to a cautious outlook. The stock has experienced erratic trading, not trading on four out of the last twenty days, which may indicate reduced investor interest. Furthermore, there has been a notable decline in delivery volume, which fell by 52.58% against the five-day average, suggesting weakening investor participation. The sector itself, Medical Equipment/Supplies/Accessories, has seen a decline of 3.03%, which could be impacting the stock's performance.<BR><BR>From a fundamental perspective, the company faces challenges, including a negative book value and a high debt-to-equity ratio, indicating weak long-term financial strength. While the stock has performed well in the short term, the underlying financial issues, such as stagnant operating profit and a significant drop in profits over the past year, raise concerns about its sustainability.<BR><BR>In summary, while Span Divergent Ltd has shown strong performance in the short term and reached a new high, the combination of erratic trading, declining investor participation, and fundamental weaknesses suggests that the stock may face challenges moving forward.

Which are the latest news on Span Divergent?